Hans De Haard

This inventor holds 20 USPTO granted patents and 14 published patent applications, plus 1 CIPO patent and 4 EPO patents, primarily in Immunotherapy Antibodies. Top assignees: Ablynx N.v., Staten Biotechnology B.v., Argenx Bv. Active years: 2016-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hans De Haard. Retrieved from https://idiyas.com/inventor/hans-de-haard

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 20 (Patent Applications = 14)

% Patents Active = 85.0

CIPO Patents = 1

EPO Patents = 4 (Patent Applications = 11)

Average Co-Inventor Count = 3.6

ph-index = 3

Forward Citations = 27(Granted Patents)

Company Filing History:

Staten Biotechnology B.v.

Ludwig Institute for Cancer Research Limited

patents

6. 2 out of 100

Universitè Catholique De Louvain

where one patent can have more than one assignee

Years Active: 2016-2025

Loading Chart...

Areas of Expertise:

Immunotherapy

Antibodies

Amino Acid Sequences

Anti-ApoC3

Anti-Kv1.3

Human Complement Factor

Polynucleotides

Tumor Necrosis Factor-alpha

GARP Protein

Immune System Modulation

Single Domain Antibodies

Pulmonary Administration

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12202900 - Compositions and methods for treating immune thrombocytopenia (2025-01-21),

2. 11858997 - Amino acid sequences that modulate the interaction between cells of the immune system (2024-01-02),

3. 11708403 - Antibodies to human complement factor C2B and methods of use (2023-07-25),

4. 11597763 - Anti-Kv1.3 antibodies, and methods of production and use thereof (2023-03-07),

5. 11591386 - Antibodies to human complement C2B (2023-02-28),

6. 11248042 - Polynucleotides encoding anti-ApoC3 antibodies (2022-02-15),

7. 11248041 - Anti-ApoC3 antibodies (2022-02-15),

8. 11242381 - Anti-ApoC3 antibodies and methods of use thereof (2022-02-08),

9. 11230603 - Anti-GARP protein (2022-01-25),

10. 11161900 - Antibodies that specifically bind to human complement factor C2b (2021-11-02),

11. 11091539 - Anti-ApoC3 antibodies and methods of use thereof (2021-08-17),

12. 11066473 - Galectin-10 antibodies (2021-07-20),

13. 10844123 - Amino acid sequences that modulate the interaction between cells of the immune system (2020-11-24),

14. 10604579 - Antibody against a complex between human GARP and latent TGF-β (2020-03-31),

15. 10538583 - Anti-APOC3 antibodies and compositions thereof (2020-01-21),

Title: The Innovative Journey of Hans de Haard

Introduction: Hans de Haard, a visionary inventor hailing from Oudelande, NL, has made significant contributions to the field of technology through his groundbreaking inventions and patents.

Latest Patents: De Haard's latest patents include cutting-edge advancements in biotechnology, particularly in the development of novel gene editing techniques for medical applications.

Career Highlights: With a career spanning over two decades, Hans de Haard has established himself as a leading figure in the innovation landscape. His work has not only revolutionized the biotech industry but has also paved the way for future advancements in the field.

Collaborations: Throughout his career, de Haard has collaborated with top research institutions, universities, and biotech companies to further his research and bring his inventions to life. His collaborative spirit has led to the successful development and commercialization of several groundbreaking technologies.

Conclusion: In conclusion, Hans de Haard's relentless pursuit of innovation and his passion for pushing the boundaries of what is possible have solidified his position as a trailblazing inventor in the world of biotechnology. His contributions continue to inspire and shape the future of the industry.

Profile summary based on public USPTO records.